Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

There is now considerable evidence that human tumors often express antigens that render them susceptible to lysis by cytotoxic T lymphocytes (CTLs). These findings have raised hope for the development of cancer vaccines to trigger a tumor-specific immune response in cancer patients. To optimize the immunogenicity of cancer vaccines, it is important to improve the monitoring of the immune response. The use of tetrameric soluble major histocompatibility complex (MHC) class I/peptide complexes ("tetramers") to identify tumor-specific CTLs has shown that these novel reagents allow rapid and accurate analysis of human CTL responses in cancer patients. We have used fluorescence-driven cell sorting to clone tumor-specific CTLs after staining with tetrameric MHC class I/peptide complexes. Analysis of melanoma-infiltrated lymph nodes revealed that strong CTL responses often occur in vivo, and that the reactive CTLs have substantial proliferative and tumoricidal potential.


Journal article


Cancer Chemother Pharmacol

Publication Date



46 Suppl


S83 - S85


Antigens, Neoplasm, Epitopes, T-Lymphocyte, Flow Cytometry, HLA Antigens, HLA-A2 Antigen, Histocompatibility Antigens Class I, Humans, Lymph Nodes, MART-1 Antigen, Melanocytes, Melanoma, Monitoring, Immunologic, Neoplasm Proteins, T-Lymphocytes, Cytotoxic, Vitiligo, beta 2-Microglobulin